Archive for the ‘Bio-Rad Product Highlight’ Category
Bio-Rad Laboratories, Inc. announced the release of its Bio-Plex Manager MP Software Upgrade, which runs on all Luminex-based MAGPIX readers. Users of Bio-Rad’s Bio-Plex® MAGPIX™ instruments have already benefited from the ease of use and improved instrument performance that Bio-Plex Manager MP software brings to multiplex experiments, and now, with Bio-Plex Manager MP Software Upgrade, these benefits are available on all Luminex-based MAGPIX readers.
Over the past decade and a half, life science researchers have relied on Luminex bead-based immunoassays to gain more information from less sample in less time. Bio-Rad’s years of experience with xMAP technology have provided the company with in-depth knowledge and an understanding of the needs of multiplex users, including their desire for automation and a simplified user experience.
The Bio-Plex Manager MP Software Upgrade brings the benefits of Bio-Plex Manager MP software, including automated instrument management, to all Luminex-based MAGPIX readers.
Bio-Plex Manager MP software offers an automated instrument management function, a unique feature that guides routine maintenance of the instrument based on its current status and performance. This automated feature ensures high quality data and optimal performance by:
- Automatically loading start-of-day maintenance routines based on instrument status
- Monitoring performance during data acquisition, alerting the user of performance issues, and resolving those issues
- Recommending simple stepwise troubleshooting
All of these benefits are now available for all Luminex-based MAGPIX readers through the Bio-Plex Manager MP Software Upgrade.
For more information on Bio-Rad’s Bio-Plex product portfolio, please visit www.bio-rad.com/bioplex.
High purity protein is a common requirement for biochemical and structural studies. A common approach is to recombinantly express an affinity-tagged version of the protein of interest. This is, however, not always a viable option. Some proteins are unstable or inactive once tagged or require posttranslational modifications that do not permit recombinant expression. In these cases, researchers often settle for lower purity protein rather than exhaustively explore purification options, since the purification optimization process can be time and labor intensive when no particular column resins or buffer conditions are dictated by an affinity tag.
Bio-Rad Laboratories has recently released a study demonstrating how to purify untagged protein to high homogeneity without undergoing laborious manual troubleshooting steps. Bio-Rad’s ChromLab software can be programmed to execute several runs sequentially thereby automating and accelerating this tedious process.
To learn how to purify untagged protein with ease read Protein Purification Workflow Development Using Bio-Rad’s NGC™ Chromatography System.
Bio-Rad Laboratories announced the launch of more than 700 new PrimePCR human and mouse disease panels and 71 new pathway panels for real-time PCR (qPCR). The panels allow researchers to thoroughly and efficiently investigate genes known to be differentially expressed in a specified pathology or biological pathway. Bio-Rad now offers more than 1,100 panels with nearly 6,700 predesigned plate configurations, establishing Bio-Rad as the industry’s largest and most up-to-date provider of predesigned plates.
The expanded product line includes highly studied pathways such as Hedgehog and bone morphogenetic protein (BMP) signaling, as well as processes such as circadian rhythms and visual perception. In addition, disease categories span hundreds of conditions, ranging from specific cancers and neoplasms to metabolic diseases such as obesity and diabetes.
Working in collaboration with Thomson Reuters, Bio-Rad developed a plate design strategy that ensures that the most relevant gene targets are chosen for each real-time PCR panel; gene targets are weighted for differentially expressed genes and the frequency with which they appear in the peer-reviewed literature. For disease panels, Thomson Reuters referenced the diseases and their corresponding gene targets in the U.S. National Library of Medicine database.
All of the assays were designed strictly adhering to MIQE guidelines: maximum transcript coverage, minimal overlap with known single nucleotide polymorphisms, and spanning large introns where possible. In addition, all of the primer assays have been fully wet-lab validated for specificity, efficiency, and sensitivity to an unprecedented level of quality, according to Jan Hellemans, cofounder of the qPCR and bioinformatics firm Biogazelle, which worked with Bio-Rad to develop these assays.
Bio-Rad has also updated and expanded its existing predesigned pathway and collection panels to include the most scientifically relevant gene targets based on current literature and the latest bioinformatics data.
For more information on Bio-Rad’s PrimePCR products, please visit www.bio-rad.com/PrimePCR.